An adaptive Phase 1/2a of IDL-2965 evaluating safety, PK, and biomarker-based proof of mechanism in in healthy volunteers
Latest Information Update: 26 Apr 2019
At a glance
- Drugs IDL 2965 (Primary)
- Indications Idiopathic pulmonary fibrosis; Non-alcoholic steatohepatitis
- Focus Adverse reactions; Biomarker; Pharmacokinetics
- Sponsors Indalo Therapeutics
- 18 Apr 2019 According to an Indalo Therapeutics media release, first healthy volunteer has been dosed in a Phase 1 clinical trial.
- 18 Apr 2019 Status changed from planning to recruiting according to an Indalo Therapeutics media release.
- 04 Feb 2019 New trial record